You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants
|
|---|---|
| Published in |
Critical Care, February 2017
|
| DOI | 10.1186/s13054-017-1619-z |
| Pubmed ID | |
| Authors |
Matthias Ebner, Ingvild Birschmann, Andreas Peter, Charlotte Spencer, Florian Härtig, Joachim Kuhn, Gunnar Blumenstock, Christine S. Zuern, Ulf Ziemann, Sven Poli |
| Abstract |
Point-of-care testing (POCT) of coagulation has been proven to be of great value in accelerating emergency treatment. Specific POCT for direct oral anticoagulants (DOAC) is not available, but the effects of DOAC on established POCT have been described. We aimed to determine the diagnostic accuracy of Hemochron® Signature coagulation POCT to qualitatively rule out relevant concentrations of apixaban, rivaroxaban, and dabigatran in real-life patients. We enrolled 68 patients receiving apixaban, rivaroxaban, or dabigatran and obtained blood samples at six pre-specified time points. Coagulation testing was performed using prothrombin time/international normalized ratio (PT/INR), activated partial thromboplastin time (aPTT), and activated clotting time (ACT+ and ACT-low range) POCT cards. For comparison, laboratory-based assays of diluted thrombin time (Hemoclot) and anti-Xa activity were conducted. DOAC concentrations were determined by liquid chromatography-tandem mass spectrometry. Four hundred and three samples were collected. POCT results of PT/INR and ACT+ correlated with both rivaroxaban and dabigatran concentrations. Insufficient correlation was found for apixaban. Rivaroxaban concentrations at <30 and <100 ng/mL were detected with >95% specificity at PT/INR POCT ≤1.0 and ≤1.1 and ACT+ POCT ≤120 and ≤130 s. Dabigatran concentrations at <30 and <50 ng/mL were detected with >95% specificity at PT/INR POCT ≤1.1 and ≤1.2 and ACT+ POCT ≤100 s. Hemochron® Signature POCT can be a fast and reliable alternative for guiding emergency treatment during rivaroxaban and dabigatran therapy. It allows the rapid identification of a relevant fraction of patients that can be treated immediately without the need to await the results of much slower laboratory-based coagulation tests. Unique identifier, NCT02371070 . Retrospectively registered on 18 February 2015. |
X Demographics
The data shown below were collected from the profiles of 43 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 7 | 16% |
| United States | 5 | 12% |
| Chile | 2 | 5% |
| Italy | 2 | 5% |
| Mexico | 1 | 2% |
| Canada | 1 | 2% |
| Greece | 1 | 2% |
| Argentina | 1 | 2% |
| France | 1 | 2% |
| Other | 1 | 2% |
| Unknown | 21 | 49% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 26 | 60% |
| Practitioners (doctors, other healthcare professionals) | 7 | 16% |
| Scientists | 6 | 14% |
| Science communicators (journalists, bloggers, editors) | 4 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 76 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 9 | 12% |
| Student > Ph. D. Student | 8 | 11% |
| Student > Bachelor | 8 | 11% |
| Researcher | 7 | 9% |
| Other | 6 | 8% |
| Other | 12 | 16% |
| Unknown | 26 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 33% |
| Nursing and Health Professions | 6 | 8% |
| Biochemistry, Genetics and Molecular Biology | 4 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Neuroscience | 3 | 4% |
| Other | 6 | 8% |
| Unknown | 29 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 25. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 March 2017.
All research outputs
#1,417,067
of 23,978,545 outputs
Outputs from Critical Care
#1,266
of 6,283 outputs
Outputs of similar age
#34,722
of 460,709 outputs
Outputs of similar age from Critical Care
#32
of 76 outputs
Altmetric has tracked 23,978,545 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,283 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.3. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 460,709 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 76 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.